Holen Sie sich die Stockscreener-App
23.74
4.70%
-1.171
Handel nachbörslich:
23.76
0.021
+0.09%
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna (MRNA): Assessing Valuation as Cancer Therapy Pipeline Expands with New Multiple Myeloma Trial - Yahoo Finance
Should You Buy Moderna Stock Ahead of Q3 Earnings Report? - sharewise.com
Here’s why Moderna is sliding - Traders Union
17,216 Shares in Moderna, Inc. $MRNA Purchased by Corton Capital Inc. - MarketBeat
Can Moderna Inc. stock hit record highs againWeekly Stock Summary & Long-Term Growth Stock Strategies - newser.com
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - USA Today
Nisa Investment Advisors LLC Sells 23,279 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Inc. Stock Slides 8.3%, Underperforms Peers - 富途牛牛
Revaccination With mRNA-1345 for RSV Maintains Robust Immunogenicity, Safety - Vaccine Advisor
Moderna begins first patient dosing in multiple myeloma trial - Investing.com India
Moderna, Inc. (MRNA) Stock Forecasts - Yahoo Finance
Inside Biotech: Moderna opens new front in oncology with T-cell engager therapy - Proactive financial news
Moderna Stock Is Sliding Monday: What's Going On? - Benzinga
Moderna Stock Falls on Revenue Decline and Clinical Trial SetbackNews and Statistics - IndexBox
Why Moderna (MRNA) Stock Is Falling Today - Yahoo Finance
Moderna (MRNA) Begins Phase 1/2 Trial for mRNA-2808 in Multiple Myeloma - GuruFocus
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Tacoma News Tribune
Moderna (NASDAQ: MRNA) starts Phase 1/2 trial dosing mRNA-2808 for multiple myeloma - Stock Titan
Moderna, Inc. $MRNA Shares Sold by South Dakota Investment Council - MarketBeat
Will Moderna Inc. stock benefit from sector rotationDollar Strength & Growth Oriented Trade Recommendations - newser.com
Moderna, Inc. (NASDAQ:MRNA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Is it too late to sell Moderna Inc.2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Is Moderna Inc. stock in correction or buying zoneAnalyst Upgrade & Risk Controlled Daily Trade Plans - newser.com
How moving averages guide Moderna Inc. tradingJuly 2025 Rallies & AI Powered Buy and Sell Recommendations - newser.com
Moderna Stock Soars 13.93%, Hits Intraday High of $29.20 - Markets Mojo
GAM Holding AG Invests $276,000 in Moderna, Inc. $MRNA - MarketBeat
Wealthfront Advisers LLC Has $521,000 Stake in Moderna, Inc. $MRNA - MarketBeat
New York Life Investment Management LLC Acquires 31,327 Shares of Moderna, Inc. $MRNA - MarketBeat
Applying Wyckoff theory to Moderna Inc. stock2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
Moderna’s Mysterious Exit Sparks Acquisition Frenzy—What’s Really Happening? - Smartkarma
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - York Dispatch
Y Intercept Hong Kong Ltd Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Sumitomo Mitsui Trust Group Inc. Trims Holdings in Moderna, Inc. $MRNA - MarketBeat
Asset Management One Co. Ltd. Reduces Stock Position in Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock benefits from tech adoptionJuly 2025 Catalysts & Detailed Earnings Play Strategies - newser.com
Moderna (NASDAQ:MRNA) Stock Price Up 9.5%Time to Buy? - MarketBeat
Moderna Stock Falls, Reversing Some Buyout Rally Gains | 2025News and Statistics - IndexBox
Why Moderna (MRNA) Stock Is Trading Lower Today - Yahoo Finance
Moderna: Focus On Cancer Vaccines, Not Buyout (NASDAQ:MRNA) - Seeking Alpha
Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On?Moderna (NASDAQ:MRNA) - Benzinga
Moderna (MRNA) Stock Retreats After Acquisition Speculation Surge - GuruFocus
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Best data tools to analyze Moderna Inc. stockWeekly Stock Report & Precise Buy Zone Identification - newser.com
Why Moderna Inc. stock is favored by top institutions2025 Stock Rankings & Daily Entry Point Trade Alerts - newser.com
Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength? - Nasdaq
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline - sharewise.com
Is Moderna Inc. meeting your algorithmic filter criteriaJuly 2025 PreEarnings & Low Risk High Reward Ideas - newser.com
Will Moderna Inc. stock gain from strong economyWeekly Profit Summary & Safe Capital Investment Plans - newser.com
Using Ichimoku Cloud for Moderna Inc. technicalsForecast Cut & Daily Profit Focused Screening - newser.com
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - columbiadailyherald.com
Moderna Ignites Biotech Sector with Deal Talk Surge Amidst Broader Healthcare Woes - FinancialContent
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges - Investopedia
Moderna (MRNA) Stock Rallies on Rumors of Potential Takeover Deal - parameter.io
Moderna Stock Rallies On Reports Of Company Entering Talks With A Drugmaker For A Potential Deal - Stocktwits
Moderna soars after STAT reports “a buyout or a large partnership” are on the table - Sherwood News
Moderna to Present at Upcoming Conferences in September 2025 - Iowa City Press-Citizen
Moderna gains on report it held talks with at least one large drugmaker (MRNA:NASDAQ) - Seeking Alpha
Moderna Q2 2025 slides: Revenue falls 41% as company pivots to diversified pipeline - Investing.com
Moderna gains on report it held talks with at least one large drugmaker (update) - MSN
Moderna rises after report on potential deal talks - TradingView
Moderna (MRNA) Considers Potential Buyout in Discussions with Ma - GuruFocus
Moderna (MRNA) Shares Surge Amid Potential Major Deal Talks - GuruFocus
Moderna jumps almost 11% on big deal rumors - breakingthenews.net
Earnings call transcript: Moderna sees Q2 2025 revenue drop, stock surges - Investing.com
Moderna (MRNA) Experiences Notable Increase in Morning Trading - GuruFocus
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - Kewanee Star Courier
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):